Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Government Payers Health Technology Assessment Market Access

Drug Pricing Alliances Expand In Europe

  • News

Executive Summary

Slovenia has joined the Valletta group, with Croatia set to follow. Meanwhile, Ireland has formally signaled its interest in joining the BeNeLuxA collaboration.

You may also be interested in...



EU Cross-Country Coalition Targets New Products For Joint Pricing Talks

The BeNeLuxAI initiative was among the many topics covered at the DIA Europe 2019 conference in Austria last week. The cross-country coalition has some new drugs in its sights for joint pricing talks and the conference was given an insight into the workings of the collaboration by a Belgian health department advisor close to the initiative.

BeNeLuxA Cooperation Embraces Ireland & Moves Forward On Patient Registries

Ireland is set to join Belgium, the Netherlands, Luxembourg and Austria as part of the BeNeLuxA collaboration.

Greece Calls For Sharper Teeth for Valletta Group As Croatia Enlists

The Valletta group of southern EU states on improving access to medicines continues to expand and now includes Croatia.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
Government Payers Health Technology Assessment Market Access
Latest Headlines

US FDA’s June User Fee Calendar Starts Out Steady, But A Crescendo Of Decisions Will Start Mid-Month

Supplemental Filings: FDA Expands In-Person Meeting Eligibility Again; Marks Suggests Sponsors Invite Foreign Regulators To FDA Meetings

Diabetes Drugs: US FDA Proposes Hypoglycemia Efficacy Endpoints, With Limits

FDA, Medicare And The Future Of Coverage With Evidence Development For Accelerated Approvals

See All
UsernamePublicRestriction

Register

PS122520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By